Venous thromboembolism in menopausal period - part one

Grzegorz Stachowiak; Ireneusz Połać; Ludomir Stefańczyk; Sławomir Jędrzejczyk; Tomasz Pertyński; Tomasz Stetkiewicz

Abstract

5/2004 vol. 3

Venous thromboembolism in menopausal period - part one

Grzegorz Stachowiak

,

Ireneusz Połać

,

Ludomir Stefańczyk

,

Sławomir Jędrzejczyk

,

Tomasz Pertyński

,

Tomasz Stetkiewicz

Prz Menopauz 2004; 5: 57-62

Online publish date: 2004/10/22

View full text

AMA

Stachowiak G, Połać I, Stefańczyk L, Jędrzejczyk S, Pertyński T, Stetkiewicz T. Venous thromboembolism in menopausal period - part one. Menopause Review/Przegląd Menopauzalny. 2004;3(5):57-62.

APA

Stachowiak, G., Połać, I., Stefańczyk, L., Jędrzejczyk, S., Pertyński, T., & Stetkiewicz, T. (2004). Venous thromboembolism in menopausal period - part one. Menopause Review/Przegląd Menopauzalny, 3(5), 57-62.

Chicago

Stachowiak, Grzegorz, Ireneusz Połać, Ludomir Stefańczyk, Sławomir Jędrzejczyk, Tomasz Pertyński, and Tomasz Stetkiewicz. 2004. "Venous thromboembolism in menopausal period - part one". Menopause Review/Przegląd Menopauzalny 3 (5): 57-62.

Harvard

Stachowiak, G., Połać, I., Stefańczyk, L., Jędrzejczyk, S., Pertyński, T., and Stetkiewicz, T. (2004). Venous thromboembolism in menopausal period - part one. Menopause Review/Przegląd Menopauzalny, 3(5), pp.57-62.

MLA

Stachowiak, Grzegorz et al. "Venous thromboembolism in menopausal period - part one." Menopause Review/Przegląd Menopauzalny, vol. 3, no. 5, 2004, pp. 57-62.

Vancouver

Stachowiak G, Połać I, Stefańczyk L, Jędrzejczyk S, Pertyński T, Stetkiewicz T. Venous thromboembolism in menopausal period - part one. Menopause Review/Przegląd Menopauzalny. 2004;3(5):57-62.

In this article an important topic of menopausal gynecology – venous thromboembolism (VTE) – has been analyzed. In the first part we have paid attention to VTE risk factors being characteristic for menopausal period as well as to some changes in female organism causing rise in VTE risk. One part of the article has also been spent on the influence of hormonal therapy of climacterium – both oral contraception and hormone replacement therapy – on thromboembolic complications, particularly in women with thrombophilia.